Arcellx, Inc. (ACLX)
Largest Insider Buys in Sector
ACLX Stock Price History Chart
ACLX Stock Performance
About Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid …
Insider Activity of Arcellx, Inc.
Over the last 12 months, insiders at Arcellx, Inc. have bought $0 and sold $91.4M worth of Arcellx, Inc. stock.
On average, over the past 5 years, insiders at Arcellx, Inc. have bought $182.5M and sold $92.63M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 312,500 shares for transaction amount of $5M was made by BASKETT FOREST () on 2022‑06‑21.
List of Insider Buy and Sell Transactions, Arcellx, Inc.
| 2024-10-22 | Sale | director | 1,500 0.0028% | $89.69 | $134,535 | 0.00% | ||
| 2024-10-01 | Sale | director | 1,500 0.0027% | $82.24 | $123,360 | +5.84% | ||
| 2024-09-17 | Sale | CHIEF FINANCIAL OFFICER | 15,000 0.0278% | $77.73 | $1.17M | +9.89% | ||
| 2024-09-10 | Sale | director | 1,500 0.0028% | $74.41 | $111,615 | +13.07% | ||
| 2024-09-05 | Sale | CHIEF MEDICAL OFFICER | 3,421 0.0063% | $70.02 | $239,526 | +17.86% | ||
| 2024-09-03 | Sale | CHIEF MEDICAL OFFICER | 27,451 0.0518% | $67.03 | $1.84M | +25.38% | ||
| 2024-08-26 | Sale | CHIEF MEDICAL OFFICER | 21,684 0.0399% | $71.13 | $1.54M | +12.86% | ||
| 2024-08-20 | Sale | director | 1,500 0.0028% | $65.88 | $98,820 | +20.49% | ||
| 2024-08-16 | Sale | CHIEF MEDICAL OFFICER | 5,450 0.0112% | $65.05 | $354,526 | +2.03% | ||
| 2024-08-01 | Sale | CHIEF MEDICAL OFFICER | 20,000 0.0385% | $60.42 | $1.21M | +29.97% | ||
| 2024-07-30 | Sale | director | 1,500 0.0028% | $61.97 | $92,949 | -5.35% | ||
| 2024-07-16 | Sale | CHIEF MEDICAL OFFICER | 10,901 0.0248% | $65.30 | $711,854 | +12.67% | ||
| 2024-07-12 | Sale | CHIEF MEDICAL OFFICER | 1,780 0.0037% | $60.21 | $107,175 | 0.00% | ||
| 2024-07-11 | Sale | CHIEF MEDICAL OFFICER | 3,671 0.0077% | $60.01 | $220,302 | 0.00% | ||
| 2024-07-09 | Sale | director | 1,500 0.003% | $56.63 | $84,947 | 0.00% | ||
| 2024-07-01 | Sale | CHIEF MEDICAL OFFICER | 20,000 0.0386% | $55.39 | $1.11M | 0.00% | ||
| 2024-06-27 | Sale | director | 10,000 0.0189% | $54.27 | $542,657 | 0.00% | ||
| 2024-06-26 | Sale | CHIEF FINANCIAL OFFICER | 12,877 0.0241% | $53.70 | $691,519 | +38.33% | ||
| 2024-06-12 | Sale | CHIEF MEDICAL OFFICER | 20,000 0.0382% | $55.13 | $1.1M | +27.81% | ||
| 2024-05-24 | Sale | CHIEF FINANCIAL OFFICER | 12,121 0.0227% | $50.71 | $614,656 | +28.05% |
Insider Historical Profitability
| Carroll Jill | director | 1479148 2.7516% | $93.51 | 1 | 6 | +6.58% |
| New Enterprise Associates 15, L.P. | 10 percent owner | 6745262 12.548% | $93.51 | 2 | 0 | +40.21% |
| Novo Holdings A/S | 10 percent owner | 4016878 7.4725% | $93.51 | 1 | 0 | +6.58% |
| SR ONE CAPITAL MANAGEMENT, LLC | 10 percent owner | 1658780 3.0858% | $93.51 | 1 | 1 | +6.58% |
| BASKETT FOREST | director | 0 0% | $93.51 | 1 | 1 | +73.84% |
Institutional Investor Ownership
| Fidelity Investments | $375.19M | 10.08 | 5.39M | +23.18% | +$70.62M | 0.03 | |
| Perceptive Advisors | $273.58M | 7.35 | 3.93M | -13.45% | -$42.51M | 0.18 | |
| Paradigm BioCapital Advisors LP | $265.55M | 7.14 | 3.82M | +4.36% | +$11.09M | 9.63 | |
| Nea Management Company Llc | $260.48M | 7 | 3.75M | 0% | +$0 | 1.22 | |
| BlackRock | $213.25M | 5.73 | 3.07M | +1.57% | +$3.31M | 0.01 |